{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Ophthalmologic (Uveitis) Adverse Event Management', 'Uveitis', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Discontinue REGN2810', 'Evaluation by an ophthalmologist is strongly', 'recommended.', 'if symptoms persist', 'despite treatment with', 'Treat with topical steroids such as 1%', 'Grade 1', 'topical', 'prednisolone acetate suspension and', 'iritis, iridocyclitis', 'immunosuppressive', 'iridocyclitics.', 'therapy', 'Discontinue REGN2810', 'if symptoms persist', 'Evaluation by an ophthalmologist is strongly', 'All attempts should', 'despite treatment with', 'recommended.', 'be made to rule out', 'topical', 'Treat with topical steroids such as 1%', 'other causes such as', 'Grade 2', 'immunosuppressive', 'prednisolone acetate suspension and', 'metastatic disease,', 'therapy and do not', 'iridocyclitics.', 'infection, or other', 'improve to Grade 1', 'ocular disease', 'within the retreatment', '(e.g., glaucoma or', 'period OR requires', 'cataracts).', 'systemic treatment.', 'Treat with systemic corticosteroids such as', 'prednisone at a dose of 1-2 mg/kg per day. When', 'Grade 3-4', 'Discontinue REGN2810', 'symptoms improve to <Grade 1, steroid taper', 'should be started and continued over no less than', '4 weeks', 'Regeneron Pharmaceuticals, Inc.', 'Page 130 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Nausea and Vomiting Adverse Event Management', 'Nausea and', 'REGN2810 Dosing', 'Diagnostic', 'Vomiting', 'Action and Guidelines', 'Management', 'Considerations', 'CTCAE v4.0 Grade', 'Grade 1', 'No change in dose', 'Hold until <Grade 1.', 'Resume at same dose', 'level. May increase', 'Grade 2', 'dosing interval by 1', 'week if it takes more', 'Nausea and vomiting should be treated', 'than 4 weeks for', 'aggressively, and consideration should be given in', 'toxicities to resolve.', 'subsequent cycles to the administration of', 'prophylactic antiemetic therapy according to', 'Hold until <Grade 2.', 'standard institutional practice. Patients should be', 'strongly encouraged to maintain liberal oral fluid', 'May increase dosing', 'intake.', 'interval by 1 week for', 'each occurrence.', 'Grade 3', 'Discontinue if', 'toxicities do not', 'resolve within', '12 weeks.', 'Grade 4', 'Off protocol therapy', 'Regeneron Pharmaceuticals, Inc.', 'Page 131 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'APPENDIX 3. MEDDRA DICTIONARY-DERIVED PREFERRED', 'TERMS FOR POTENTIAL IRAES', 'MedDRA v23.0 Preferred Terms (N=267)', \"Addison's disease\", 'Adrenal androgen deficiency', 'Adrenal atrophy', 'Adrenal insufficiency', 'Adrenal suppression', 'Adrenocortical insufficiency acute', 'Glucocorticoid deficiency', 'Hypoaldosteronism', 'Mineralocorticoid deficiency', 'Primary adrenal insufficiency', 'Secondary adrenocortical insufficiency', 'Antinuclear antibody increased', 'Antinuclear antibody positive', 'Arthralgia', 'Arthritis', 'Autoimmune arthritis', 'Immune-mediated arthritis', 'Polyarthritis', 'Rheumatoid arthritis', 'Autoimmune demyelinating disease', 'Axonal neuropathy', 'Regeneron Pharmaceuticals, Inc.', 'Page 132 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}